Get the Stockscreener App
11.07
3.78%
-0.4349
Transcode Therapeutics Inc stock is traded at $11.07, with a volume of 28,812.
It is down -3.78% in the last 24 hours and up +27.46% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$11.51
Open:
$11.75
24h Volume:
28,812
Relative Volume:
0.53
Market Cap:
$9.40M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0416
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-0.36%
1M Performance:
+27.46%
6M Performance:
-96.29%
1Y Performance:
-95.15%
1-Day Range:
$10.45
$11.75
1-Week Range:
$10.16
$11.75
52-Week Range:
$6.1478
$739.20
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
11.28 | 9.16M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.35 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.73 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.42 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.33 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.25 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Building trade automation scripts for TransCode Therapeutics Inc.Growth Watchlist for Long Term Positioning - Newser
Understanding TransCode Therapeutics Inc.’s price movementWeekly High Conviction Trade Setup Analysis - Newser
Top Risks to Consider Before Buying TransCode Therapeutics Inc. StockMomentum Detection with Entry Optimization - Newser
Can momentum traders help lift TransCode Therapeutics Inc.Free Fundamental + Technical Hybrid Stock Tips - Newser
Using Ichimoku Cloud for TransCode Therapeutics Inc. technicalsAI Trading Forecast Based on Big Data - Newser
What makes TransCode Therapeutics Inc. stock price move sharplyReal-Time Equity Price Action Analysis - Newser
Using data models to predict TransCode Therapeutics Inc. stock movementFree AI Driven Stock Trend Forecast - Newser
When is the best time to exit TransCode Therapeutics Inc.Chart Driven Opportunity Scanner with Alerts - Newser
Is TransCode Therapeutics Inc. the Top Chart Pick This WeekTrade Scanner With Buy Zone Alerts Flagged - metal.it
Why ATCO.PRH stock attracts strong analyst attentionMarket Sentiment Tracker with Smart Alerts - Newser
Is TransCode Therapeutics Inc. a growth stock or a value stockCapitalize on momentum-driven opportunities - Jammu Links News
Does TransCode Therapeutics Inc. stock perform well during market downturnsExceptional profit margins - Jammu Links News
Is it the right time to buy TransCode Therapeutics Inc. stockTremendous return on equity - Jammu Links News
When is TransCode Therapeutics Inc. stock expected to show significant growthMaximize your portfolio’s earning potential - Jammu Links News
Why is TransCode Therapeutics Inc. stock attracting strong analyst attentionCapitalize on fast-growing investment opportunities - Jammu Links News
How does TransCode Therapeutics Inc. compare to its industry peersCapitalize on fast-moving trading opportunities - Jammu Links News
What institutional investors are buying TransCode Therapeutics Inc. stockBuild a winning investment portfolio - Jammu Links News
How volatile is TransCode Therapeutics Inc. stock compared to the marketUnprecedented growth rates - Jammu Links News
Relative strength of TransCode Therapeutics Inc. in sector analysisAI Screener Based Stock Summary Report - Newser
Will TransCode Therapeutics Inc. stock benefit from interest rate changesFree Low Risk Swing Trade Opportunity List - Newser
Using RSI to spot recovery in TransCode Therapeutics Inc.Triple Digit Gain Opportunity Watchlist - Newser
Analyzing recovery setups for TransCode Therapeutics Inc. investorsFree Trade Setups With AI Powered Filters - Newser
Signal strength of TransCode Therapeutics Inc. stock in tech scannersWatchlist Generator With Real-Time Entry - Newser
Candlestick signals on TransCode Therapeutics Inc. stock todayOptimized Watchlist With Daily Adjustments Launched - metal.it
Will breakout in TransCode Therapeutics Inc. lead to full recoveryFree Trend Following Strategy With Stop Loss - Newser
TransCode Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEntry Optimization Tool with Screener Logic - Newser
Using flow based indicators on TransCode Therapeutics Inc.Technical Trend Forecast for Investors - Newser
Should you hold or exit TransCode Therapeutics Inc. nowMinimal Risk Growth Investment Opportunity Analysis - Newser
Real time alert setup for TransCode Therapeutics Inc. performanceVolume Spike Detection for Early Breakouts - Newser
Why TransCode Therapeutics Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it
What’s next for TransCode Therapeutics Inc. stock priceStrong Buy With Technical Confidence Supported - metal.it
Is TransCode Therapeutics Inc. Stock a Good Fit for Conservative InvestorsFree Alpha Focused Technical Trade Signals - Newser
TransCode Therapeutics Inc. stock outlook for YEARFree High Growth Low Risk Stock Selection - Newser
How does TransCode Therapeutics Inc. generate profit in a changing economyMassive portfolio appreciation - Jammu Links News
What are analysts’ price targets for TransCode Therapeutics Inc. in the next 12 monthsRapid growth trajectories - jammulinksnews.com
DSGR stock prediction for this week Free Trade Scanner With Buy Zone Alerts - Newser
Candlestick signals on TransCode Therapeutics Inc. stock today Long-Term Investment Strategy Summary Guide - Newser
How many analysts rate TransCode Therapeutics Inc. as a “Buy”Discover undervalued stocks before they soar - jammulinksnews.com
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):